Literature DB >> 15297068

Adolescent and adult pertussis vaccination: computer simulations of five new strategies.

Annelies Van Rie1, Herbert W Hethcote.   

Abstract

Approximately one million adult pertussis cases occur annually in the US, and infants still die from pertussis. Computer simulations were used to predict the impact of vaccination of children, adults and/or adolescents, and household members of newborns (cocoon strategy). Childhood vaccination greatly reduced cases in children, but increased the incidence in adolescents and adults. Routine adolescent and adult vaccination had a large direct effect, whereas the cocoon strategy had a predominantly indirect effect on young infants. The number needed to vaccinate (NNV) to prevent a case of typical pertussis in the entire population was lowest for the adolescent strategy. The cocoon strategy had the lowest NNV to prevent a case of typical pertussis in young infants. The current vaccination schedule, local epidemiological data, age-specific cost of pertussis cases, and accessibility of the target population will determine which strategy has the highest likelihood of success in achieving the public health goal.

Entities:  

Mesh:

Year:  2004        PMID: 15297068     DOI: 10.1016/j.vaccine.2004.01.067

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Interactive agent based modeling of public health decision-making.

Authors:  Amanda L Parks; Brett Walker; Warren Pettey; Jose Benuzillo; Per Gesteland; Juliana Grant; James Koopman; Frank Drews; Matthew Samore
Journal:  AMIA Annu Symp Proc       Date:  2009-11-14

2.  A modelling analysis of pertussis transmission and vaccination in Rio de Janeiro, Brazil.

Authors:  P M Luz; C T Codeço; G L Werneck; C J Struchiner
Journal:  Epidemiol Infect       Date:  2005-11-29       Impact factor: 2.451

3.  Adult pertussis vaccination strategies and their impact on pertussis in the United States: evaluation of routine and targeted (cocoon) strategies.

Authors:  L Coudeville; A van Rie; P Andre
Journal:  Epidemiol Infect       Date:  2007-07-05       Impact factor: 2.451

Review 4.  Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Authors:  Seema Mattoo; James D Cherry
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

5.  Shift in the epidemiology of pertussis infection: an indication for pertussis vaccine boosters for adults?

Authors:  Sylvia H Yeh; ChrisAnna M Mink
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  Increased awareness and health care provider endorsement is required to encourage pregnant women to be vaccinated.

Authors:  J Collins; I Alona; R Tooher; H Marshall
Journal:  Hum Vaccin Immunother       Date:  2014-11-21       Impact factor: 3.452

7.  Incidence and reproduction numbers of pertussis: estimates from serological and social contact data in five European countries.

Authors:  Mirjam Kretzschmar; Peter F M Teunis; Richard G Pebody
Journal:  PLoS Med       Date:  2010-06-22       Impact factor: 11.069

8.  Cost-Effectiveness of Pertussis Vaccination During Pregnancy in the United States.

Authors:  Katherine E Atkins; Meagan C Fitzpatrick; Alison P Galvani; Jeffrey P Townsend
Journal:  Am J Epidemiol       Date:  2016-05-13       Impact factor: 4.897

9.  Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects.

Authors:  Laurent Coudeville; Annelies Van Rie; Denis Getsios; J Jaime Caro; Pascal Crépey; Van Hung Nguyen
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240

10.  Quantifying the impact of community quarantine on SARS transmission in Ontario: estimation of secondary case count difference and number needed to quarantine.

Authors:  Susan J Bondy; Margaret L Russell; Julie Ml Laflèche; Elizabeth Rea
Journal:  BMC Public Health       Date:  2009-12-24       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.